FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol

Baebies, Inc.2,500 enrolled

Overview

The goal of this observational study is to compare the FINDER FLU A/B, RSV, SARS-CoV-2 Test to an FDA-cleared device. The study will utilize prospectively collected de-identified nasopharyngeal samples obtained from both pediatric and adult populations from subjects presenting with symptoms of respiratory illness. The main question it aims to answer are: • the study is to validate that the device intended use in terms that the device's performance meets the criteria for substantial equivalence with a predicate and satisfies the statutory criteria for Clinical Laboratory Improvement Amendments (CLIA) waiver.

Study Type

OBSERVATIONAL

Enrollment

2,500

Conditions

Influenza A Influenza Type B SARS CoV 2 Infection RSV Infection

Interventions

The FINDER FLU A/B, RSV, SARS-CoV-2 Test real-time RT-PCR test for the qualitative detection of viral RNA from RSV, FLU A, FLU B and SARS-CoV-2 in nasopharyngeal (NP) specimens from individuals suspected of respiratory tract infection by their healthcare provider. Nucleic acids from respiratory viruses identified by this test are typically detectable in nasopharyngeal swabs (NP) during the acute phase of infection. The detection and identification of specific viral nucleic acids from individuals signs is an indication of the presence of the identified microorganism and assist in the diagnosis of respiratory infection when considered alongside other clinical and epidemiological information.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Nasopharyngeal samples will be collected using swabs and placed in liquid transport media. * The samples are obtained from individuals exhibiting respiratory signs and symptoms. * These samples are collected as part of standard differential diagnostic procedures. * A minimum sample volume of 1.5 mL is required for testing purposes. Exclusion Criteria: * de-identified samples that have not been stored in accordance with CDC recommendations for nasopharyngeal (NP) sample storage. * Samples obtained from subjects who do not exhibit signs or symptoms of respiratory illness. * The sample with a volume is less than 1.5 mL

Outcomes

Primary Outcomes

Qualitative detection of viral RNA from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Influenza A (H1N1 and H3N2 subtypes), Influenza B (Victoria and Yamagata strains), and Respiratory Syncytial Virus (A and B subtypes) in nasopharyngeal (NP) specimens from individuals suspected of respiratory tract infection by their healthcare provider.for adults and pediatrics when compared to a known FDA cleared assay/ instrument combination.

Time frame: within 72 hours of collection of NP swab

Secondary Outcomes

CLIA Waived results and clinical laboratory result

Characterization of the performance of the FINDER device when used at a CLIA-waived location and when used in a clinical laboratory location.

Time frame: within 72 hours of collection of NP swab

Central Contacts

Candice Prowse

CONTACT

7038632530 clinical@baebies.com

Nikisha Harwani